Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor κB–mediated pathogenic pathways

V Swarup, D Phaneuf, N Dupré, S Petri… - Journal of Experimental …, 2011 - rupress.org
Journal of Experimental Medicine, 2011rupress.org
TDP-43 (TAR DNA-binding protein 43) inclusions are a hallmark of amyotrophic lateral
sclerosis (ALS). In this study, we report that TDP-43 and nuclear factor κB (NF-κB) p65
messenger RNA and protein expression is higher in spinal cords in ALS patients than
healthy individuals. TDP-43 interacts with and colocalizes with p65 in glial and neuronal
cells from ALS patients and mice expressing wild-type and mutant TDP-43 transgenes but
not in cells from healthy individuals or nontransgenic mice. TDP-43 acted as a co-activator of …
TDP-43 (TAR DNA-binding protein 43) inclusions are a hallmark of amyotrophic lateral sclerosis (ALS). In this study, we report that TDP-43 and nuclear factor κB (NF-κB) p65 messenger RNA and protein expression is higher in spinal cords in ALS patients than healthy individuals. TDP-43 interacts with and colocalizes with p65 in glial and neuronal cells from ALS patients and mice expressing wild-type and mutant TDP-43 transgenes but not in cells from healthy individuals or nontransgenic mice. TDP-43 acted as a co-activator of p65, and glial cells expressing higher amounts of TDP-43 produced more proinflammatory cytokines and neurotoxic mediators after stimulation with lipopolysaccharide or reactive oxygen species. TDP-43 overexpression in neurons also increased their vulnerability to toxic mediators. Treatment of TDP-43 mice with Withaferin A, an inhibitor of NF-κB activity, reduced denervation in the neuromuscular junction and ALS disease symptoms. We propose that TDP-43 deregulation contributes to ALS pathogenesis in part by enhancing NF-κB activation and that NF-κB may constitute a therapeutic target for the disease.
rupress.org